Síndrome de Sjögren y síntomas secos en pacientes con esclerosis sistémica

Alex Magno Coelho Horimoto; Vinicius de Macedo Possamai; Izaias Pereira da Costa

doi:10.47196/rar.v27i4.575

Alex Magno Coelho Horimoto Universidad Médica de Mato Grosso do Sul, Brasil
Vinicius de Macedo Possamai Universidad Médica de Mato Grosso do Sul, Brasil
Izaias Pereira da Costa Universidad Médica de Mato Grosso do Sul, Brasil

DOI: https://doi.org/10.47196/rar.v27i4.575

Palabras clave: síndrome de Sicca, síndrome de Sjögren, superposición, autoanticuerpos, esclerosis sistémica

Resumen

Introducción: Varias enfermedades autoinmunes pueden ir acompañadas de disfunción de las glándulas salivales, independientemente de la presencia o ausencia de asociación con el síndrome de Sjögren (SS). Un estudio reciente de Maeshima y sus colegas hallaron hiposecreción salival en el 58,3% de los pacientes con diversas enfermedades del tejido conectivo, particularmente la esclerosis sistémica (SSc).

Biografía del autor/a

Alex Magno Coelho Horimoto, Universidad Médica de Mato Grosso do Sul, Brasil

Reumatólogo, profesor de Reumatología

Vinicius de Macedo Possamai, Universidad Médica de Mato Grosso do Sul, Brasil

Reumatólogo

Izaias Pereira da Costa, Universidad Médica de Mato Grosso do Sul, Brasil

Reumatólogo, profesor de Reumatología

Citas

I. Herrick AL, Worthington J. Genetic epidemiology Systemic sclerosis. Arthritis Res 2002;4:165-8.

II. Varga J, Abraham D. Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest 2007;117:557-67.

III. Ramos-Casals M, Brito-Zerón P, Font J. The overlap of Sjögren’s syndrome with other systemic autoimune diseases. Semin Arthritis Rheum 2007;36:246-55.

IV. Avouac J, Sordet C, Depinay C, Ardizonne M, Vacher-Lavenu MC, Sibilia J et al. Systemic sclerosis-associated Sjögren's syndrome and relationship to the limited cutaneous subtype: results of a prospective study of sicca syndrome in 133 consecutive patients. Arthritis Rheum 2006;54:2243-9.

V. Miyawaki S, Asanuma H, Nishiyama S, Yoshinaga Y. Clinical and serological heterogeneity in patients with anti-centromere antibodies. J Rheumatol 2005; 32:1488-94.

VI. Gulatti D, Kushner I, File E, Magrey M. Primary Sjögren’s syndrome with anti-centromere antibodies – a clinically distinct subset. Clin Rheumatol 2010; 29:789-91.

VII. Baldini C, Mosca M, Della Rossa A, Pepe P, Notarstefano C, Ferro F et al. Overlap of ACA-positive systemic sclerosis and Sjögren’s syndrome: a distinct clinical entity with mild organ involvement buta t high risk of lymphoma. Clin Exp Rheumatol 2013;31:272-80.

VIII. Bournia VKK, Diamanti KD, Vlachoyannopoulos PG, Moutsopoulos HM. Anti-centromere antibody positive Sjögren’s syndrome: a retrospective descriptive analysis. Arthritis Res Ther 2010;12:R47 (http:// arthritis-research.com/content/12/2/R47).

IX. Salliot C, Mouthon L, Ardizzone M, Sibilia J, Guillevin L, Gottenberg JE et al. Sjögren’s syndrome is associated with and not secondary to systemic sclerosis. Rheumatology (Oxford) 2007;46:321-6.

X. Kobak S, Oksel F, Aksu K, Kabasakal Y. The frequency of sicca symptons and Sjögren’s syndrome in patients with systemic sclerosis. Intern J Rheum Dis 2013;16:88-92.

XI. B albir-Gurman A, Braun-Moscovici Y. Scleroderma overlap syndrome. Israel Med Assoc J 2011;13:14-20.

XII. Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A et al. 2013 classification criteria for systemic sclerosis: an American college of rhematology/ European league against rheumatism collaborative initiative. Ann Rheum Dis 2013;72:1747-55.

XIII. L eRoy EC, Medsger Jr. TA. Criteria for the Classification of Early Systemic Sclerosis. J Rheumatol 2001;28:1573-6.

XIV. Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL et al. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002;61:554-558.

XV. V alentini G, D’Angelo S, Rossa AD, Bencivelli W, Bombardieri S. European Scleroderma Study Group to define disease activity criteria for systemic sclerosis. IV. Assessment of skin thickening by modified Rodnan skin score. Ann Rheum Dis 2003;62:904-5.

XVI. Medsger Jr TA, Bombardieri S, Czirjak L, Scorza R, Della Rossa A, Bencivelli W. Assessment of disease severity and prognosis. Clin Exp Rheumatol 2003;21:42-6.

XVII. Valentini G, Della Rossa A, Bombardieri S, Bencivelli W, Silman AJ, D’Angelo S et al. European multicentre study to define disease activity criteria for systemic sclerosis. II. Identification of disease activity variables and development of preliminar activity indexes. Ann Rheum Dis 2001;60:592-8.

XVIII. Rannou F, Poiraudeau S, Berezné A, Baubet T, Le-Guern V, Cabane J et al. Assessing disability and quality of life in systemic sclerosis: construct validities of the Cochin hand function scale, health assessment questionnaire (HAQ), systemic sclerosis HAQ, and medical outcomes study 36-item short form health survey. Arthritis Rheum 2007;57:94-102.

XIX. Dellavance A, Gabriel Jr. A, Cintra AFU, Ximenes AC, Nuccitelli B, Tabilerti BH et al. II Consenso Brasileiro de Fator Antinuclear em células Hep-2. Rev Bras Reumatol 2003;43:129-40.

XX. McClain MT, Ramsland PA, Kaufman KM, James JA. Anti-Sm autoantibodies in systemic lupus target highly basic surface structures of complexed spliceosomal autoantigens. J Immunol 2002;168:2054-62.

XXI. A dams LE, Spencer-Green G, Donovan-Brand R, Mcenergy P, Hayden L, Hess EV et al. Comparison of four rheumatoid fator assays. Clin Labor Sci (Washington, DC) 1988;1:362-5.

XXII. S ato S, Hamaguchi Y, Hasegawa M, Takehara K. Clinical significance of anti-topoisomerase I antibody levels determined by ELISA in systemic sclerosis. Rheum 2001;40:1135-40.

XXIII. Codullo V, Morozzi G, Bardoni A, Salvini R, Deleonardi G, Pità O et al. Validationof a new immuno enzymatic method to detect antibodies to RNA polymerase III in systemic sclerosis. Clin Exp Rheumatol 2007;25:373-7.

XXIV. SHOTT, S. Statistics for health professionals. London: W.B. Saunders Company 1990.

XXV. Maeshima E, Furukawa K, Maeshima S, Koshiba H, Sakamoto W. Hyposalivation in autoimune diseases. Rheumatol Int 2013;33:3079-82.

XXVI. Szigeti N, Fábián G, Czirják L. Fatal scleroderma renal crisis caused by gastrointestinal bleeding in a patient with scleroderma, Sjögren’s syndrome and primary biliaty cirrhosis overlap. JEADV 2002;16:276-9.

XXVII. A naya JM, Tobon GJ, Veja P, Castiblanco J. Autoimmune disease aggregation in families with primary Sjögren’s syndrome. J Rheumatol 2006; 33:2227-34.

XXVIII. Hervier B, Lambert M, Hachulla E, Muset L, Benvniste O, Piette JC et al. Anti-synthetase syndrome positive for anti-isoleucyl-tRNA synthetase antibodies: an unusual case overlapping with systemic sclerosis and Sjögren’s syndrome. Rheumatology 2011;50:1175-6.

XXIX. Nakamura T, Higashi S, Tomoda K, Tsukano M, Sugi K. Primary biliary cirrhosis (PBC) - CREST overlap syndrome with coexistence of Sjögren’s syndrome and thyroid dysfunction. Clin Rheumatol 2007;26:596-600.

XXX. Hanafusa T, Igawa K, Kotobuki Y, Kitaba S, Tani M, Katayama I. Systemic lymphadenopathy with systemic sclerosis and Sjogren’s syndrome: a case report. Jap Dermatol Assoc 2012;18:124-5.

XXXI. Kogawa H, Migita K, Ito M, Takii Y, Daikoku M, Nakao M et al. Idiopathic portal hypertension associated with systemic sclerosis and Sjögren’s syndrome. Clin Rheumatol 2005;24:544-7.

XXXII. Y amamoto T, Nishioka K. Coexistence of psoriasis vulgaris, systemic sclerosis and anular erytjema in association with Sjögren’s syndrome. J Dermatol 2004;31:69-72.

XXXIII. M ellemkjaer L, Pfeiffer RM, Engels EA, Gridley G, Wheeler W, Hemminki K et al. Autoimmune disease in individuals and close Family members and susceptibility to non-Hodgkin’s lymphoma. Arthritis Rheum 2008;58:657-66.

XXXIV. García-Carrasco M, Sisó A, Ramos-Casals M, Tosas J, delaRed G, Gil V et al. Raynaud’s phenomenon in primary Sjögren’s syndrome. Prevalence and clinical characteristics in a series of 320 patients. J Rheumatol 2002;29:726-30.

XXXV. W uttge DM, Lood C, Tufvesson E, Scheja A, Truedsson L, Bengtsson AA et al. Increased serum type I interferon activity in early systemic sclerosis patients associated with antibodies against Sjogren’s syndrome antigens and nuclear ribonucleoprotein antigens. Scand J Rheumatol 2013;42:235-40.